Insomnia

Compared with normal sleepers, those with poor sleep and insomnia showed a significant association with lower flow-mediated disease levels, the most common method to describe endothelial dysfunction.

In subanalyses of ISI responders with chronic insomnia, those in the lemborexant 10-mg group demonstrated significantly greater changes from baseline in sleep onset latency compared with placebo.

The IDSIQ showed score changes that correlated with clinically meaningful improvement on various responder definition estimates following triangulation.